eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | central retinal vein occlusion |
| Symptom | |macular edema |
| Sentences | 51 |
| PubMedID- 25902119 | Patients and methods: we describe a retrospective series of patients followed in the medical retina unit of the jules gonin eye hospital for macular edema due to ischemic central retinal vein occlusion, refractory to monthly retreatment with ranibizumab, and changed to aflibercept. |
| PubMedID- 19967679 | Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. |
| PubMedID- 22668313 | Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion. |
| PubMedID- 22991926 | Retinal function and morphology in central retinal vein occlusion with macular edema. |
| PubMedID- 21087958 | Predictors of short-term visual outcome after anti-vegf therapy of macular edema due to central retinal vein occlusion. |
| PubMedID- 21538003 | Vitreous inflammatory factors in macular edema with central retinal vein occlusion. |
| PubMedID- 22823029 | Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (vegf), is widely used for the treatment of macular edema associated with central retinal vein occlusion (crvo). |
| PubMedID- 23379834 | Changes of macular sensitivity and morphology after pars plana vitrectomy for macular edema with central retinal vein occlusion: a case series. |
| PubMedID- 24531560 | Association of electroretinogram and morphological findings in central retinal vein occlusion with macular edema. |
| PubMedID- 23433821 | We report the case of anterior chamber migration of a dexamethasone implant (ozurdex((r))) in a 54-year-old woman with macular edema due to a central retinal vein occlusion. |
| PubMedID- 22044337 | Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. |
| PubMedID- 26117932 | The paper presents the first results concerning the aflibercept (eylea) treatment, the last antivegf approved for treatment of the age related macular degeneration (amd), neovascular form and for macular edema due to the central retinal vein occlusion. |
| PubMedID- 25576994 | Purpose: to review the available evidence regarding the safety and efficacy of therapies for the treatment of macular edema (me) associated with central retinal vein occlusion (crvo). |
| PubMedID- 22105941 | To investigate whether vitreous fluid levels of vascular endothelial growth factor (vegf), pigment epithelium-derived factor (pedf), and soluble intercellular adhesion molecule 1 (sicam-1) influence visual prognosis and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 24847256 | We report a 19-year-old patient who developed a central retinal vein occlusion (crvo) with significant macular edema and visual impairment following intense exercise and dehydration. |
| PubMedID- 20827142 | Purpose: the purpose of this study was to evaluate the effect of intravitreal triamcinolone acetonide on macular function in cases of macular edema because of central retinal vein occlusion. |
| PubMedID- 25634982 | Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema. |
| PubMedID- 24999721 | Methods: a retrospective review of six consecutive cases of central retinal vein occlusion with persistent macular edema despite regular anti-vascular endothelial growth factor injections that were transitioned to aflibercept was conducted. |
| PubMedID- 24828198 | Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections. |
| PubMedID- 20432959 | Short-term effects of intravitreal injection of bevacizumab on macular edema due to central retinal vein occlusion. |
| PubMedID- 23713337 | Ozurdex, modern therapy for macular edema in central retinal vein occlusion. |
| PubMedID- 22925843 | Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide. |
| PubMedID- 21764136 | Objective: to evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (dex implant) over 12 months in eyes with macular edema owing to branch or central retinal vein occlusion (brvo or crvo). |
| PubMedID- 23764703 | This new technique is a promising treatment of macular edema due to central retinal vein occlusion. |
| PubMedID- 23629792 | Patients and methods: eyes with a macular edema due to a central retinal vein occlusion or to a branch retinal vein occlusion were considered if at least 3 intravitreal injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) had been performed. |
| PubMedID- 19763601 | Background: to evaluate prognostic factors of response to intravitreal bevacizumab therapy of macular edema (me) due to central retinal vein occlusion (crvo) or branch retinal vein occlusion (brvo). |
| PubMedID- 22615698 | Resolution of persistent cystoid macular edema due to central retinal vein occlusion in a vitrectomized eye following intravitreal implant of dexamethasone 0.7 mg. |
| PubMedID- 22424833 | Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. |
| PubMedID- 21978179 | Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. |
| PubMedID- 23690676 | Unilateral macular edema with central retinal vein occlusion in systemic lupus erythematosus: a case report. |
| PubMedID- 23709332 | Macular pseudohole development after sustained-release dexamethasone intravitreal implant for macular edema due to central retinal vein occlusion. |
| PubMedID- 23673531 | Objective: to review the pharmacology, efficacy, and safety data available for aflibercept and compare the drug to other therapeutic options for treatment of macular edema following central retinal vein occlusion (crvo) to determine its likely role in therapy. |
| PubMedID- 24940042 | Aims: to determine if intravitreal bevacizumab combined with the dexamethasone intravitreal implant 0.7 mg improves visual acuity and macular thickness more than bevacizumab monotherapy in eyes with macular edema due to branch and central retinal vein occlusions. |
| PubMedID- 22606470 | We report our unusual experience while treating a case of hemicentral retinal vein occlusion with macular edema. |
| PubMedID- 21598607 | Medium-term effects of intravitreal bevacizumab for macular edema associated with central retinal vein occlusion. |
| PubMedID- 22562161 | macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity. |
| PubMedID- 20453544 | The outcome of vitrectomy for macular edema was examined in patients with central retinal vein occlusion (crvo), as well as whether vascular endothelial growth factor (vegf) and interleukin-6 (il-6) levels in vitreous fluid influence the visual prognosis and macular edema. |
| PubMedID- 21350277 | A comparative study between intravitreal triamcinolone and bevacizumab for macular edema due to central retinal vein occlusion with poor vision. |
| PubMedID- 25383828 | Results: initial ophthalmic examination showed bilateral central retinal vein occlusion with macular edema, including serous macular detachment in the left eye. |
| PubMedID- 20935688 | Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment. |
| PubMedID- 24205253 | Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. |
| PubMedID- 25902116 | Recurrent macular edema in central retinal vein occlusion treated with intravitreal ranibizumab using a modified treat and extend regimen. |
| PubMedID- 20658459 | The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). |
| PubMedID- 23046435 | Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. |
| PubMedID- 24688266 | The score (standard care vs corticosteroid for retinal vein occlusion) study revealed the benefit of steroid treatment in central retinal vein occlusion (crvo) associated with macular edema (me) 1. |
| PubMedID- 22824616 | Clinical findings and investigations confirmed nonischemic central retinal vein occlusion (crvo) with persisting macular edema. |
| PubMedID- 22824618 | A comparative study between intravitreal triamcinolone and bevacizumab for macular edema due to central retinal vein occlusion with poor vision. |
| PubMedID- 21275514 | Purpose: to investigate whether pigment epithelium-derived factor (pedf) or vascular endothelial growth factor (vegf) influences macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 22902212 | Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. |
| PubMedID- 24325604 | Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series. |
Page: 1 2